HDAC and methyltransferase inhibitors are able to restore functional ERα in breast cancer cells, and re-sensitise the cell lines to anti-oestrogen therapies such as tamoxifen and fulvestrant. This evidence concerns the gene HDAC9 and breast carcinoma.